Imidocarb: a chemoprophylactic experiment with Babesia canis.
Eight dogs, given imidocarb dipropionate subcutaneously at a dose of 6 mg/kg, were challenged with a sporozoite stabilate of a French strain of Babesia canis, prepared from infected Dermacentor reticulatus ticks, 2, 3, 4 or 5 weeks after treatment. Three control dogs were similarly infected but not preventively treated. One of the controls and one of the dogs treated 5 weeks prior to challenge died of babesiosis. Prepatent and incubation periods were similar in treated and control dogs, and all dogs showed important reductions in the packed cell volume. Relapses were commonly seen after recovery from the initial reaction. Although further work is needed before a final conclusion can be drawn to whether imidocarb is suitable as a chemoprophylactic against B. canis infection, it can be used as a curative drug.
D000578:Amidines / Q000008:administration & dosage; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D001404:Babesiosis / Q000517:prevention & control*; D002224:Carbanilides / Q000008:administration & dosage*; D004133:Diminazene / Q000008:administration & dosage / Q000031:analogs & derivatives; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D006400:Hematocrit; D007095:Imidocarb / Q000008:administration & dosage* / Q000031:analogs & derivatives; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008297:Male
D000578:Amidines; D000981:Antiprotozoal Agents; D002224:Carbanilides; D007095:Imidocarb; C001772:amicarbalide diisethionate; C003915:diminazene aceturate; D004133:Diminazene; C031719:imidocarb dipropionate